The French experience

Slides adapted from Dr Hélène Fontaine, Hepatology Unit, Hôpital Cochin, Paris
Scaling-up screening

- 2001: people with a high risk of contamination
- 2014-2016: men 18-60 years and pregnant women (1st trimester)
- Since 2016: all adults
Scaling-up access to treatment

2013: patients with severe fibrosis or cirrhosis

2014: patients with severe fibrosis or cirrhosis and/or severe extra-hepatic manifestations

2016: patients with significant fibrosis, extra-hepatic manifestations and/or a risk factor of rapid progression of fibrosis

January 2017: UNIVERSAL ACCESS
Progressive availability of DAAs through « temporary authorisation for use » (ATU)
Journée nationale de lutte contre les hépatites B et C, 25 mai 2016

« Aujourd’hui, je décide l’accès universel aux traitements de l’hépatite C. »

Marisol Touraine
Ministre des Affaires Sociales, de la Santé et des droits des femmes
25 mai 2016
Simplified management of HCV treatment
French Guidelines 2018 - AFEF

For patients without:
- Severe fibrosis or cirrhosis at Fibroscan, Fibrotest or Fibrometer
- HBV and/or HCV coinfection
- Severe renal insufficiency
- Uncontrolled liver comorbidities (excessive alcohol consumption, diabetes, obesity)
Official communication on the National Health Strategy – March 2018

Scaling-up prevention and screening in the most exposed populations to contribute to HCV elimination in France in 2025.

Objectives:
• Eliminate hepatitis C in 2025

Measures:
• Improve the relationships between hospital and non-hospital care management and favor prescription of anti-HCV therapies by all HCPs
• Reinforce screening with rapid diagnostic tests for HBV, HCV, and HIV
• Reinforce prevention as close as possible to the patient, particularly prioritize people who are away from the usual health system
Applications in France

• « Go to » strategies in drug centers, sexual health centers, social centers with development of « test and treat » strategies including the use of Fibroscan

• Micro-elimination actions
  • in geographical areas (regions, towns such as Montpellier or smaller cities)
  • In care centers ( hospital, drug user center, social center...)
  • Coordination of actions between patient associations (SOS Hepatites) and hepatologists
« Point-of-Care » *versus* « Laboratory centered » ?

**Def. « Lab.centered »**

“POC testing is defined as testing performed close to or near the patient, i.e. where healthcare is provided outside of traditional centralised laboratories »

**Def. « POC »**

Chevaliez & Pawlotsky, *J Hepatol* 2018
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study

The adjusted multivariable analyses show that DAA treatment is associated with a rapid decrease in all-cause mortality and the incidence of hepatocellular carcinoma, and that these inverse associations are stronger in patients with cirrhosis.
« Parcours » study

Results in 488 patients: 86% males, 46 years-old, 87% current or past IVDU, 67% OST, 28% migrants, 18% prisonners, 38% comorbidities (17% psychiatric, 7% HIV and 3% HBV coinfection)

**Screening**
- Strong promotion of screening in high-risk populations
- Venipuncture or RDT, or DBS
- Screening days

**Linkage to care**
- Specialized consultation in the same week
- Support in the social and medical process
- Promotion of consultation with a specialist

**Treatment and follow-up**
- Coordination of care by a dedicated team of medical-social workers;
- Integrated management with therapeutic education, addictological orientation

Bachelard A et al, AFEF 2018
Results in 488 patients: 86% males, 46 years-old, 87% current or past IVDU, 67% OST, 28% migrants, 18% prisoners, 38% comorbidities (17% psychiatric, 7% HIV and 3% HBV coinfection)

Fibrosis stage (n=297)
Evaluation by FibroScan® or FibroTest®

- F0–F1: 51.5%
- F2: 13.8%
- F3: 13.5%
- F4: 21.2%

« Parcours » study

- Number of people, n
- Virological response, %

- All patients: 488
- PCR reported: 387
- HCV RNA +: 332
- Followed: 326
- Treatment initiated: 259
- EOT: 97.9%
- SVR12: 94.8%

Bachelard A et al, AFEF 2018
French communication campaign

#DUeBRUITCONTReL'HéPATITEC
75 000 personnes ignorent qu'elles ont l'hépatite C
(j'ai écrit très gros pour que tout le monde le sache)

Sans un bruit, l'hépatite C peut détruire votre foie.
Sortez l'hépatite C du silence. Faites-vous dépister.

© ESCMID eLibrary by author
Du bruit contre l’hépatite C

NATIONAL CAMPAIGN FOR GENERAL POPULATION AND HEALTH WORKERS

PRESS MAGAZINES

SOCIAL MEDIA

LE MONDE

AFEF WEBSITE

#DUBRUITCONTRELHEPATITEC
#HEPATITEC

TV + VIDEO ONLINE

RAILWAY STATIONS